Skip to main content
Global Bioenergies logo

Global Bioenergies — Investor Relations & Filings

Ticker · ALGBE ISIN · FR0011052257 LEI · 969500H46XRAMTMVB676 PA Manufacturing
Open in API
Filings indexed 443 across all filing types
Latest filing 2022-09-15 Regulatory Filings
Country FR France
Listing PA ALGBE

About Global Bioenergies

https://www.global-bioenergies.com/?lan…

Global Bioenergies develops and commercializes a process to convert renewable resources, such as plant-based sugars and agricultural waste, into isobutene. The company's proprietary technology utilizes fermentation and synthetic biology to produce this key hydrocarbon, which serves as a platform molecule for various applications. The bio-isobutene can be converted into ingredients for the cosmetics industry, specialty chemicals, and renewable fuels. A primary strategic focus is the production of Sustainable Aviation Fuel (SAF) to support the decarbonization of the aviation sector. The process provides a bio-based alternative to petroleum-derived hydrocarbons, aiming to reduce CO2 emissions and dependence on fossil fuels.

Recent filings

Filing Released Lang Actions
Global Bioenergies fait le point sur sa situation et ses perspectives
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) multiple times. It provides an update on the company's situation and perspectives, detailing progress across four horizons (production scales, market entry for cosmetics, and future plans for materials/fuels). This format, which is an update on operations, strategy, and outlook, is characteristic of a general corporate announcement or press release, rather than a formal regulatory filing like a 10-K, an earnings release (ER) which focuses strictly on period results, or a detailed Investor Presentation (IP). Since it is a general update disseminated via press release, and it doesn't fit the specific definitions for AGM-R, AR, MANG, CT, CAP, DVA, DLST, DIRS, SR, FS, CGR, IRAT, IR, LTR, TAR, MRQ, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements or press releases that don't fit elsewhere, although 'Press Release' itself is not a primary code. Given the options, RNS is the best fit for a general corporate update distributed as a press release that isn't a core financial report or specific event announcement.
2022-09-15 French
Bilan semestriel du contrat de liquidité au 30/06/2022
Capital/Financing Update Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité au 30/06/2022" (Semi-annual statement of the liquidity contract as of 06/30/2022). It details the status of a liquidity contract (share buyback/stabilization agreement) managed by a broker (Gilbert Dupont), showing the number of shares and cash held at the reporting date, and the transactions executed during the first half of 2022. This type of filing specifically reports on the company's own share transactions for market stabilization purposes, which directly corresponds to the definition of 'Transaction in Own Shares' (POS). It is not a general earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it focuses narrowly on the share repurchase/liquidity program.
2022-07-11 French
Bernard Chaud élu Président de l’Association de la Chimie du Végétal
Board/Management Information Classification · 99% confidence The document is a press release dated June 22, 2022, announcing that Bernard Chaud, an executive from Global Bioenergies, has been elected President of the Association de la Chimie du Végétal (ACDV). This announcement concerns a change in leadership/position within an industry association involving a company executive. This fits the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management, extended here to include significant external leadership roles taken by key personnel. It is not an earnings release (ER), a formal regulatory filing (like 10-K), or a dividend notice (DIV). It is a specific announcement about management personnel.
2022-06-22 French
Global Bioenergies secures first order from Shell for testing volumes of bio-isobutene derivatives
Regulatory Filings Classification · 95% confidence The document is a press release dated June 21, 2022, announcing a specific business event: Global Bioenergies securing its first order from Shell for bio-isobutene derivatives. It details a commercial agreement and provides company background. This type of announcement, which is a specific operational or commercial update but not a mandatory regulatory filing like a 10-K, ER, or IR, fits best under the general category for regulatory announcements or news releases that don't fit elsewhere. Since it is a formal announcement of a business development, and not a transcript (CT), management change (MANG), or dividend notice (DIV), the most appropriate classification is Regulatory Filings (RNS) as a general news release/announcement, or potentially a Capital/Financing Update (CAP) if the order implied significant capital structure change, which it does not explicitly. Given the content is a news update about a commercial order, RNS is the best fit as a general regulatory announcement/press release.
2022-06-21 English
Global Bioenergies : Shell commande des dérivés de bio-isobutène pour la réalisation de tests
Regulatory Filings Classification · 95% confidence The document is titled 'COMMUNIQUE DE PRESSE' (Press Release) and announces a specific business event: 'Shell commande des dérivés de bioisobutène pour la réalisation de tests' (Shell orders bio-isobutene derivatives for testing). This is a short, timely announcement about a commercial transaction and partnership exploration, not a comprehensive financial report (like 10-K or IR), a transcript (CT), or a formal regulatory filing detailing ownership changes or dividends. It fits best as a general regulatory announcement or press release that doesn't fit a more specific category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release announcing business developments, although 'Report Publication Announcement' (RPA) is sometimes used for announcements, this document is announcing a *transaction*, not the publication of a report. Therefore, RNS is the best fit as a general announcement.
2022-06-21 French
Global Bioenergies annonce avoir reçu des premières commandes de plusieurs grands acteurs de la cosmétique représentant au total plusieurs tonnes d’Isonaturane® 12
Regulatory Filings Classification · 90% confidence The document is a press release dated June 7, 2022, announcing that Global Bioenergies has received initial orders for its product, Isonaturane® 12, from several major cosmetics players, including L'Oréal. This is a specific business update regarding commercial activity and product sales, not a mandatory regulatory filing like a 10-K, an earnings release (ER), or a formal capital/financing update (CAP). It is an announcement of a significant business event/transaction. Since there is no specific category for 'Commercial Update' or 'Sales Announcement', and it is not a standard regulatory filing, it falls best under the general 'Regulatory Filings' (RNS) category as a significant, non-standard corporate announcement, or potentially 'Capital/Financing Update' (CAP) if the orders imply a major shift in revenue outlook, but the focus here is on product commercialization and initial orders, making RNS the most appropriate general fit for non-standard announcements.
2022-06-07 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.